Abstract
Cilostazol improves walking distance in peripheral arterial disease (PAD) patients. The study objectives were to assess the effects of cilostazol on walking distance, followed by the additional assessment of cilostazol on exercise-induced ischaemia–reperfusion injury in such patients.
PAD patients were prospectively recruited to a double-blinded, placebo-controlled trial. Patients were randomised to receive either cilostazol 100
mg or placebo twice a day. The primary end-point was an improvement in walking distance. Secondary end-points included the assessment of oxygen-derived free-radical generation, antioxidant consumption and other markers of the inflammatory cascade. Initial and absolute claudication distances (ICDs and ACDs, respectively) were measured on a treadmill. Inflammatory response was assessed before and 30
min post-exercise by measuring lipid hydroperoxide, ascorbate, α-tocopherol, β-carotene, P-selectin, intracellular and vascular cell-adhesion molecules (I-CAM and V-CAM), thromboxane B
2 (TXB
2), interleukin-6, interleukin-10, high-sensitive C-reactive protein (hsCRP), albumin–creatinine ratio (ACR) and urinary levels of p75TNF receptor. All tests were performed at baseline and 6 and 24 weeks.
One hundred and six PAD patients (of whom 73 were males) were recruited and successfully randomised from December 2004 to January 2006. Patients who received cilostazol demonstrated a more significant improvement in the mean percentage change from baseline in ACD (77.2% vs. 26.6% at 6 weeks,
p
=
0.026 and 161.7% vs. 79.0% at 24 weeks,
p
=
0.048) as compared to the placebo. Cilostazol reduced lipid hydroperoxide levels compared to a placebo-related increase before and after exercise (6 weeks: pre-exercise: −11.8% vs. +5.8%,
p
=
0.003 and post-exercise: −12.3% vs. +13.9%,
p
=
0.007 and 24 weeks: pre-exercise −15.5% vs. +12.0%,
p
=
0.025 and post-exercise: −9.2% vs. +1.9%,
p
=
0.028). β-Carotene levels were significantly increased in the cilostazol group, compared to placebo, before exercise at 6 and 24 weeks (6 weeks: 34.5% vs. −7.4%,
p
=
0.028; 24 weeks: 34.3% vs. 17.7%,
p
=
0.048). Cilostazol also significantly reduced P-selectin, I-CAM and V-CAM levels at 24 weeks as compared to baseline (
p
<
0.05). There was no difference between treatment groups for ascorbate, α-tocopherol, interleukin-6 and -10, hsCRP and p75TNF receptor levels.
Cilostazol significantly improves ACD, in addition to attenuating exercise-induced ischaemia–reperfusion injury, in PAD patients.